GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dermapharm Holding SE (LTS:0A5J) » Definitions » Research & Development

Dermapharm Holding SE (LTS:0A5J) Research & Development : €0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Dermapharm Holding SE Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Dermapharm Holding SE's Research & Development for the three months ended in Dec. 2024 was €0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was €0 Mil.


Dermapharm Holding SE Research & Development Historical Data

The historical data trend for Dermapharm Holding SE's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermapharm Holding SE Research & Development Chart

Dermapharm Holding SE Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.66 14.17 13.18 10.63 11.54

Dermapharm Holding SE Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Dermapharm Holding SE Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dermapharm Holding SE  (LTS:0A5J) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Dermapharm Holding SE Research & Development Related Terms

Thank you for viewing the detailed overview of Dermapharm Holding SE's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Dermapharm Holding SE Business Description

Traded in Other Exchanges
Address
Lil-Dagover-Ring 7, Grunwald, BY, DEU, 82031
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.

Dermapharm Holding SE Headlines

No Headlines